Filgrastim
Filgrastim stimulates the production of white blood in bone marrow. itused to increase the white blood cell production in patient of cancer therapy whose bone marrow function is depressed by cytotoxic therapy. italso being used in the treatment of AIDS.
Primary Characteristics
It is of Semi Synthetic origin and belongs to Polypeptide.
It belongs to Granulocyte colony stimulating factor agonist pharmacological group on the basis of mechanism of action and also classified in Colony Stimulating Factor pharmacological group. It is also classified under Hematological Agents .
Molecular Weight: 18799 · Non-proprietary name: Filgrastim · pH: 4.
Pharmacokinetics
Distribution: Filgrastim has a volume of distribution is 0.15 l/kg. plasma protein binding is high.
Elimination: it is metabolised via extensive by Kidneys, plasma half-life is 1.8-3.5 hr, renal excretion is >97%.
Advertisement
Indications
Filgrastim is primarily indicated in conditions like Cytotoxic-induced neutropenia, Mobilisation of peripheral blood progenitor cells, Myeloablative therapy followed by bone marrow transplantation, Neutropenia, Persistant neutropenia in advanced hiv infection, Severe chronic neutropenia.
Filgrastim is also indicated for secondary conditions like AIDS, Aplastic anemia, Myelodysplastic syndrome.
Contraindications
Filgrastim is contraindicated in conditions like Myeloblastic leukemia.
Dosage
Filgrastim's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 5 ug/ kg | 5 ug/ kg | Every 24h | SC,IV Inf | As an adjunct to chemotherapy, starting not less than 24 hrs after the last dose of antineoplstic. |
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| 7.5 ug/kg | 7.5 ug/kg | Every 24h | Oral | Forr 3----5 days |
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
Filgrastim in overdosage may give rise to further complications which include Vasculitis , Myelogenous leukemia, Leukocytoclastic, Neutrophillic dermatitis.
Filgrastim produces potentially life-threatening effects which include Proliferation of myelogenous cells, Leukemic crisis. Careful monitoring is needed with proper medical management.
The signs and symptoms that are produced after acute overdosage of Filgrastim are Bone pain, Elevation of alkaline phosphatase, Elevation of LDH .
Filgrastim is known to cause more or less tolerable side effects which are usually transient. These include Fever, Medullary bone pain, Skin rash.
Warnings / Precautions
Available Brands
Click on a strength to view available brands.
Single Ingredient
Storage Conditions
Drug Classification
- 1.10.4 — Anabolics & hematopoietics